| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Myeloproliferative Disorders | 7 | 2021 | 507 | 2.48 | Why? |
| Primary Myelofibrosis | 12 | 2019 | 144 | 2.38 | Why? |
| Thrombocythemia, Essential | 10 | 2021 | 141 | 2.06 | Why? |
| Polycythemia Vera | 10 | 2019 | 113 | 2.03 | Why? |
| Serum Amyloid P-Component | 3 | 2021 | 193 | 1.55 | Why? |
| Hematopoietic Stem Cell Transplantation | 17 | 2019 | 2426 | 1.32 | Why? |
| Janus Kinase 2 | 5 | 2017 | 218 | 1.26 | Why? |
| Leukemia, Myeloid, Acute | 6 | 2021 | 676 | 1.00 | Why? |
| Neoplasm, Residual | 3 | 2017 | 147 | 0.97 | Why? |
| Cytokine-Induced Killer Cells | 2 | 2018 | 8 | 0.91 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 1573 | 0.89 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2019 | 526 | 0.85 | Why? |
| Complement Pathway, Mannose-Binding Lectin | 1 | 2020 | 44 | 0.84 | Why? |
| Transplantation, Homologous | 12 | 2019 | 757 | 0.73 | Why? |
| Chromosome Aberrations | 2 | 2018 | 54 | 0.70 | Why? |
| Lymphoma, Non-Hodgkin | 1 | 2021 | 403 | 0.69 | Why? |
| Lymphocyte Transfusion | 1 | 2017 | 26 | 0.69 | Why? |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2018 | 314 | 0.68 | Why? |
| Calreticulin | 1 | 2017 | 38 | 0.67 | Why? |
| Mutation | 10 | 2018 | 12376 | 0.63 | Why? |
| Thrombotic Microangiopathies | 1 | 2020 | 335 | 0.63 | Why? |
| Pyrazoles | 5 | 2021 | 1791 | 0.62 | Why? |
| C-Reactive Protein | 4 | 2021 | 7972 | 0.61 | Why? |
| Drugs, Investigational | 1 | 2018 | 198 | 0.60 | Why? |
| Hodgkin Disease | 1 | 2018 | 204 | 0.59 | Why? |
| Interleukin-8 | 1 | 2021 | 964 | 0.58 | Why? |
| Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 176 | 0.56 | Why? |
| Withholding Treatment | 1 | 2021 | 798 | 0.55 | Why? |
| Drug Resistance, Neoplasm | 2 | 2018 | 447 | 0.55 | Why? |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2019 | 82 | 0.50 | Why? |
| Philadelphia Chromosome | 4 | 2019 | 38 | 0.49 | Why? |
| Antineoplastic Agents | 7 | 2020 | 3550 | 0.47 | Why? |
| Rituximab | 3 | 2017 | 1096 | 0.47 | Why? |
| Antibodies, Monoclonal | 4 | 2021 | 8041 | 0.47 | Why? |
| Multiple Myeloma | 2 | 2018 | 1064 | 0.47 | Why? |
| Antibodies, Bispecific | 3 | 2018 | 207 | 0.44 | Why? |
| Protein Kinase Inhibitors | 3 | 2020 | 1585 | 0.39 | Why? |
| Endothelium, Vascular | 1 | 2020 | 1751 | 0.37 | Why? |
| Ventilators, Mechanical | 1 | 2021 | 2193 | 0.37 | Why? |
| Stem Cell Transplantation | 4 | 2017 | 531 | 0.34 | Why? |
| Graft vs Host Disease | 4 | 2018 | 501 | 0.33 | Why? |
| Cyclophosphamide | 2 | 2019 | 387 | 0.31 | Why? |
| Chromosome Deletion | 2 | 2017 | 62 | 0.31 | Why? |
| Transplantation Conditioning | 2 | 2017 | 323 | 0.29 | Why? |
| Doxorubicin | 2 | 2018 | 313 | 0.29 | Why? |
| Pyrimidines | 6 | 2021 | 1557 | 0.28 | Why? |
| Antibodies, Monoclonal, Murine-Derived | 2 | 2016 | 94 | 0.28 | Why? |
| Disease-Free Survival | 6 | 2019 | 1654 | 0.28 | Why? |
| Myelodysplastic Syndromes | 2 | 2017 | 261 | 0.27 | Why? |
| Leukemia | 3 | 2018 | 598 | 0.27 | Why? |
| Antineoplastic Agents, Immunological | 3 | 2021 | 830 | 0.26 | Why? |
| Prognosis | 14 | 2021 | 32490 | 0.25 | Why? |
| Remission Induction | 4 | 2018 | 950 | 0.23 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2020 | 877 | 0.23 | Why? |
| Cytogenetic Analysis | 2 | 2017 | 21 | 0.23 | Why? |
| Hematologic Neoplasms | 3 | 2021 | 2105 | 0.23 | Why? |
| Salvage Therapy | 3 | 2018 | 417 | 0.22 | Why? |
| Homozygote | 2 | 2016 | 230 | 0.22 | Why? |
| Survival Rate | 6 | 2021 | 9206 | 0.22 | Why? |
| Mannose-Binding Protein-Associated Serine Proteases | 1 | 2020 | 41 | 0.22 | Why? |
| Bone Marrow Neoplasms | 1 | 2021 | 60 | 0.21 | Why? |
| Inflammation | 3 | 2020 | 13255 | 0.21 | Why? |
| Biomarkers, Tumor | 3 | 2018 | 1314 | 0.21 | Why? |
| Nitriles | 3 | 2021 | 1053 | 0.21 | Why? |
| Acute Disease | 6 | 2021 | 6029 | 0.20 | Why? |
| Gene Expression Profiling | 3 | 2020 | 3788 | 0.20 | Why? |
| Phenotype | 4 | 2018 | 4037 | 0.20 | Why? |
| Heparin Lyase | 1 | 2018 | 7 | 0.19 | Why? |
| Genetic Association Studies | 3 | 2018 | 559 | 0.19 | Why? |
| Vinblastine | 1 | 2018 | 48 | 0.19 | Why? |
| Antilymphocyte Serum | 1 | 2018 | 80 | 0.19 | Why? |
| Dacarbazine | 1 | 2018 | 67 | 0.18 | Why? |
| Repressor Proteins | 2 | 2017 | 232 | 0.18 | Why? |
| Survival Analysis | 5 | 2018 | 7592 | 0.18 | Why? |
| Middle Aged | 38 | 2021 | 270681 | 0.18 | Why? |
| Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 86 | 0.18 | Why? |
| Chromosomes, Human, Pair 5 | 1 | 2017 | 38 | 0.18 | Why? |
| Neoplasms, Second Primary | 1 | 2019 | 100 | 0.18 | Why? |
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 43 | 0.18 | Why? |
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2017 | 14 | 0.18 | Why? |
| Blast Crisis | 1 | 2018 | 41 | 0.18 | Why? |
| B7 Antigens | 1 | 2017 | 18 | 0.18 | Why? |
| DNA Mutational Analysis | 2 | 2017 | 581 | 0.18 | Why? |
| Prostaglandin D2 | 1 | 2017 | 24 | 0.18 | Why? |
| Clonal Evolution | 1 | 2017 | 55 | 0.17 | Why? |
| Tetrahydroisoquinolines | 1 | 2017 | 12 | 0.17 | Why? |
| Recurrence | 5 | 2019 | 3675 | 0.17 | Why? |
| Dioxoles | 1 | 2017 | 19 | 0.17 | Why? |
| Treatment Outcome | 10 | 2021 | 51732 | 0.17 | Why? |
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2016 | 11 | 0.17 | Why? |
| Leukemia, Myelomonocytic, Juvenile | 1 | 2017 | 27 | 0.17 | Why? |
| Bleomycin | 1 | 2018 | 195 | 0.17 | Why? |
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 127 | 0.17 | Why? |
| Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 37 | 0.17 | Why? |
| Antineoplastic Agents, Alkylating | 1 | 2017 | 71 | 0.16 | Why? |
| Vincristine | 1 | 2016 | 89 | 0.16 | Why? |
| Humans | 65 | 2021 | 930598 | 0.16 | Why? |
| Complement C3b Inactivator Proteins | 1 | 2016 | 11 | 0.16 | Why? |
| Male | 40 | 2021 | 367725 | 0.16 | Why? |
| Female | 41 | 2021 | 380317 | 0.16 | Why? |
| Immunologic Deficiency Syndromes | 1 | 2021 | 368 | 0.16 | Why? |
| Aged | 28 | 2021 | 215776 | 0.16 | Why? |
| Phlebotomy | 1 | 2017 | 131 | 0.15 | Why? |
| Cell- and Tissue-Based Therapy | 2 | 2017 | 422 | 0.15 | Why? |
| Neoplasms | 5 | 2018 | 17251 | 0.15 | Why? |
| Lymphoma, B-Cell | 1 | 2017 | 166 | 0.15 | Why? |
| Spleen | 2 | 2018 | 877 | 0.14 | Why? |
| Genetic Predisposition to Disease | 4 | 2018 | 4027 | 0.14 | Why? |
| Follow-Up Studies | 4 | 2021 | 17020 | 0.14 | Why? |
| Hematopoietic Stem Cells | 2 | 2017 | 321 | 0.14 | Why? |
| Tumor Suppressor Protein p53 | 1 | 2017 | 310 | 0.14 | Why? |
| Sterilization | 1 | 2017 | 294 | 0.14 | Why? |
| Fetal Blood | 1 | 2018 | 573 | 0.14 | Why? |
| Europe | 6 | 2021 | 12702 | 0.14 | Why? |
| Translocation, Genetic | 1 | 2013 | 40 | 0.13 | Why? |
| Invasive Fungal Infections | 1 | 2018 | 274 | 0.13 | Why? |
| Myeloid-Derived Suppressor Cells | 1 | 2017 | 316 | 0.13 | Why? |
| Multimodal Imaging | 1 | 2018 | 534 | 0.13 | Why? |
| Combined Modality Therapy | 3 | 2018 | 3395 | 0.13 | Why? |
| Gram-Negative Bacteria | 1 | 2017 | 473 | 0.12 | Why? |
| Adult | 29 | 2020 | 244371 | 0.12 | Why? |
| Neoplasm Proteins | 1 | 2018 | 501 | 0.12 | Why? |
| Age Factors | 5 | 2020 | 21039 | 0.12 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2017 | 398 | 0.12 | Why? |
| Aged, 80 and over | 15 | 2021 | 88759 | 0.12 | Why? |
| Prednisone | 1 | 2016 | 652 | 0.12 | Why? |
| Sequence Deletion | 1 | 2016 | 674 | 0.11 | Why? |
| Renal Insufficiency | 1 | 2018 | 810 | 0.11 | Why? |
| Tissue Donors | 2 | 2018 | 1679 | 0.11 | Why? |
| Allografts | 3 | 2019 | 761 | 0.11 | Why? |
| Point Mutation | 1 | 2013 | 481 | 0.10 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.10 | Why? |
| Retrospective Studies | 10 | 2021 | 105322 | 0.10 | Why? |
| Cryopreservation | 1 | 2013 | 464 | 0.10 | Why? |
| Immunosuppressive Agents | 2 | 2018 | 6331 | 0.10 | Why? |
| Hypereosinophilic Syndrome | 1 | 2009 | 33 | 0.10 | Why? |
| Adolescent | 13 | 2019 | 86841 | 0.10 | Why? |
| Genotype | 2 | 2018 | 4697 | 0.10 | Why? |
| Unrelated Donors | 2 | 2019 | 187 | 0.09 | Why? |
| Macrophages | 1 | 2020 | 2784 | 0.09 | Why? |
| Molecular Targeted Therapy | 1 | 2018 | 1579 | 0.09 | Why? |
| Young Adult | 12 | 2018 | 93724 | 0.08 | Why? |
| Enzyme Inhibitors | 1 | 2018 | 1881 | 0.08 | Why? |
| Risk Factors | 9 | 2021 | 71621 | 0.08 | Why? |
| Italy | 10 | 2021 | 38444 | 0.08 | Why? |
| Needs Assessment | 1 | 2017 | 2352 | 0.08 | Why? |
| Thrombocytopenia | 2 | 2017 | 2093 | 0.08 | Why? |
| Transplantation, Autologous | 2 | 2018 | 364 | 0.08 | Why? |
| Adenine | 2 | 2020 | 463 | 0.08 | Why? |
| Bacteremia | 1 | 2017 | 1372 | 0.08 | Why? |
| Piperazines | 1 | 2009 | 445 | 0.08 | Why? |
| Skin Neoplasms | 1 | 2019 | 1679 | 0.07 | Why? |
| Thrombosis | 3 | 2017 | 7504 | 0.07 | Why? |
| Cell Line, Tumor | 3 | 2020 | 3608 | 0.07 | Why? |
| Heparin | 1 | 2018 | 2600 | 0.07 | Why? |
| Registries | 3 | 2019 | 12327 | 0.07 | Why? |
| Lymphocytes | 1 | 2017 | 3056 | 0.07 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.07 | Why? |
| Bone Marrow | 2 | 2018 | 492 | 0.07 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.06 | Why? |
| Piperidines | 2 | 2020 | 795 | 0.06 | Why? |
| A549 Cells | 2 | 2020 | 2066 | 0.06 | Why? |
| Caspases | 1 | 2003 | 156 | 0.06 | Why? |
| Aminoglycosides | 1 | 2003 | 94 | 0.06 | Why? |
| Leukemia, Myeloid | 1 | 2003 | 76 | 0.06 | Why? |
| Protein Kinases | 1 | 2003 | 93 | 0.06 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2021 | 4273 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Mutation, Missense | 1 | 2007 | 863 | 0.05 | Why? |
| Child | 4 | 2018 | 70012 | 0.05 | Why? |
| Risk Assessment | 4 | 2018 | 25439 | 0.05 | Why? |
| Quality of Life | 2 | 2019 | 9820 | 0.05 | Why? |
| Hemoglobins | 2 | 2017 | 958 | 0.05 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.05 | Why? |
| Sex Factors | 4 | 2021 | 11014 | 0.05 | Why? |
| Transplantation, Haploidentical | 1 | 2019 | 53 | 0.05 | Why? |
| Biomarkers | 3 | 2018 | 23361 | 0.05 | Why? |
| Cell Proliferation | 2 | 2018 | 1973 | 0.05 | Why? |
| Gene Expression Regulation, Leukemic | 1 | 2019 | 31 | 0.05 | Why? |
| Kaplan-Meier Estimate | 2 | 2021 | 4260 | 0.05 | Why? |
| Hypertension | 2 | 2021 | 8895 | 0.05 | Why? |
| K562 Cells | 1 | 2018 | 91 | 0.05 | Why? |
| Incidence | 5 | 2019 | 25622 | 0.05 | Why? |
| Nestin | 1 | 2018 | 12 | 0.05 | Why? |
| Mice, Inbred NOD | 1 | 2018 | 134 | 0.05 | Why? |
| Cohort Studies | 5 | 2021 | 36005 | 0.05 | Why? |
| Antigens, CD19 | 1 | 2018 | 98 | 0.05 | Why? |
| Mice, SCID | 1 | 2018 | 225 | 0.05 | Why? |
| HL-60 Cells | 1 | 2017 | 60 | 0.04 | Why? |
| Quinazolinones | 1 | 2019 | 135 | 0.04 | Why? |
| Matrix Metalloproteinase 2 | 1 | 2018 | 85 | 0.04 | Why? |
| Serine-Arginine Splicing Factors | 1 | 2017 | 14 | 0.04 | Why? |
| Tumor Stem Cell Assay | 1 | 2017 | 12 | 0.04 | Why? |
| Proto-Oncogene Proteins c-mdm2 | 1 | 2017 | 35 | 0.04 | Why? |
| Antigens, CD34 | 1 | 2018 | 125 | 0.04 | Why? |
| Isocitrate Dehydrogenase | 1 | 2017 | 33 | 0.04 | Why? |
| Leukocyte Count | 3 | 2017 | 3178 | 0.04 | Why? |
| Animals | 5 | 2018 | 78931 | 0.04 | Why? |
| Hematopoiesis | 1 | 2018 | 168 | 0.04 | Why? |
| Fibronectins | 1 | 2018 | 92 | 0.04 | Why? |
| Enhancer of Zeste Homolog 2 Protein | 1 | 2017 | 40 | 0.04 | Why? |
| Leukemia, Promyelocytic, Acute | 1 | 2017 | 60 | 0.04 | Why? |
| Tretinoin | 1 | 2017 | 99 | 0.04 | Why? |
| Hydroxyurea | 1 | 2017 | 87 | 0.04 | Why? |
| Splenomegaly | 1 | 2016 | 43 | 0.04 | Why? |
| Reproducibility of Results | 3 | 2019 | 11304 | 0.04 | Why? |
| Comparative Genomic Hybridization | 1 | 2016 | 33 | 0.04 | Why? |
| Cytotoxicity, Immunologic | 1 | 2018 | 287 | 0.04 | Why? |
| Hep G2 Cells | 1 | 2017 | 391 | 0.04 | Why? |
| Child, Preschool | 2 | 2017 | 36283 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.04 | Why? |
| Interleukin-13 | 1 | 2017 | 204 | 0.04 | Why? |
| Histocompatibility Antigens Class II | 1 | 2019 | 383 | 0.04 | Why? |
| Mice, Nude | 1 | 2017 | 340 | 0.04 | Why? |
| Minnesota | 1 | 2017 | 509 | 0.04 | Why? |
| Nuclear Proteins | 1 | 2018 | 321 | 0.04 | Why? |
| Janus Kinase 1 | 1 | 2017 | 254 | 0.04 | Why? |
| Megakaryocytes | 1 | 2018 | 274 | 0.04 | Why? |
| Culture Media | 1 | 2017 | 366 | 0.04 | Why? |
| Blood Component Removal | 1 | 2017 | 175 | 0.04 | Why? |
| Product Surveillance, Postmarketing | 1 | 2017 | 189 | 0.04 | Why? |
| Confidence Intervals | 1 | 2017 | 744 | 0.04 | Why? |
| Antibiotic Prophylaxis | 1 | 2017 | 399 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2019 | 15421 | 0.03 | Why? |
| Time Factors | 4 | 2018 | 31397 | 0.03 | Why? |
| Autografts | 1 | 2013 | 78 | 0.03 | Why? |
| Cell Movement | 1 | 2018 | 695 | 0.03 | Why? |
| Mice | 3 | 2018 | 21357 | 0.03 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2017 | 782 | 0.03 | Why? |
| Immunotherapy, Adoptive | 1 | 2018 | 524 | 0.03 | Why? |
| Janus Kinase Inhibitors | 1 | 2019 | 682 | 0.03 | Why? |
| Post-Exposure Prophylaxis | 1 | 2018 | 472 | 0.03 | Why? |
| Purines | 1 | 2019 | 816 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.03 | Why? |
| Protective Factors | 1 | 2018 | 1720 | 0.03 | Why? |
| Herpes Zoster | 1 | 2017 | 331 | 0.03 | Why? |
| Hematology | 1 | 2019 | 649 | 0.03 | Why? |
| Continuous Positive Airway Pressure | 1 | 2021 | 1187 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2017 | 9537 | 0.03 | Why? |
| Immunophenotyping | 1 | 2016 | 1290 | 0.03 | Why? |
| Platelet Count | 1 | 2017 | 1381 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2018 | 2739 | 0.03 | Why? |
| Gene Frequency | 1 | 2016 | 1210 | 0.03 | Why? |
| Mycoses | 1 | 2017 | 589 | 0.03 | Why? |
| mRNA Cleavage and Polyadenylation Factors | 1 | 2009 | 3 | 0.03 | Why? |
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 10 | 0.03 | Why? |
| Blood Cell Count | 1 | 2016 | 1101 | 0.03 | Why? |
| Endothelial Cells | 1 | 2020 | 2048 | 0.03 | Why? |
| Infection Control | 1 | 2019 | 23131 | 0.03 | Why? |
| Escherichia coli | 1 | 2017 | 1547 | 0.02 | Why? |
| Alleles | 1 | 2016 | 1557 | 0.02 | Why? |
| Gene Rearrangement | 1 | 2009 | 84 | 0.02 | Why? |
| Oncogene Proteins, Fusion | 1 | 2009 | 52 | 0.02 | Why? |
| Neoplasm Recurrence, Local | 1 | 2017 | 1063 | 0.02 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 1115 | 0.02 | Why? |
| Cells, Cultured | 1 | 2020 | 5835 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2019 | 2742 | 0.02 | Why? |
| Anemia | 1 | 2016 | 789 | 0.02 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.02 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
| Protein Binding | 2 | 2017 | 11430 | 0.02 | Why? |
| Killer Cells, Natural | 1 | 2018 | 2093 | 0.02 | Why? |
| Cluster Analysis | 1 | 2016 | 3001 | 0.02 | Why? |
| Monocytes | 1 | 2020 | 2978 | 0.02 | Why? |
| Noninvasive Ventilation | 1 | 2021 | 2329 | 0.02 | Why? |
| Smoking | 1 | 2021 | 3358 | 0.02 | Why? |
| Hematocrit | 1 | 2007 | 107 | 0.02 | Why? |
| Imatinib Mesylate | 1 | 2009 | 327 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Benzamides | 1 | 2009 | 421 | 0.02 | Why? |
| Heterozygote | 1 | 2007 | 249 | 0.02 | Why? |
| Organ Size | 1 | 2007 | 384 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| Hypoxia | 1 | 2021 | 3626 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Pruritus | 1 | 2007 | 215 | 0.02 | Why? |
| Myocardial Infarction | 1 | 2021 | 3361 | 0.02 | Why? |
| RNA, Messenger | 1 | 2019 | 5131 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2017 | 4002 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Interphase | 1 | 2003 | 3 | 0.02 | Why? |
| Checkpoint Kinase 2 | 1 | 2003 | 5 | 0.02 | Why? |
| G2 Phase | 1 | 2003 | 11 | 0.02 | Why? |
| Checkpoint Kinase 1 | 1 | 2003 | 10 | 0.02 | Why? |
| Neutrophils | 1 | 2020 | 5476 | 0.02 | Why? |
| Bacterial Infections | 1 | 2017 | 2229 | 0.02 | Why? |
| World Health Organization | 1 | 2017 | 4213 | 0.02 | Why? |
| Tumor Cells, Cultured | 1 | 2003 | 254 | 0.02 | Why? |
| Eosinophils | 1 | 2009 | 848 | 0.02 | Why? |
| Societies, Medical | 1 | 2019 | 6907 | 0.02 | Why? |
| Caspase 3 | 1 | 2003 | 218 | 0.02 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.02 | Why? |
| Drug Administration Schedule | 1 | 2009 | 2324 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2020 | 43792 | 0.01 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2018 | 5837 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2017 | 5150 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2003 | 10083 | 0.01 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.01 | Why? |
| Epidemics | 1 | 2020 | 6407 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 2009 | 3776 | 0.01 | Why? |
| Amino Acid Substitution | 1 | 2007 | 1706 | 0.01 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Phosphorylation | 1 | 2003 | 1060 | 0.01 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2021 | 8207 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
| Infant, Newborn | 1 | 2018 | 23105 | 0.01 | Why? |
| Models, Biological | 1 | 2013 | 4907 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2016 | 22971 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| Apoptosis | 1 | 2003 | 2335 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Pandemics | 2 | 2021 | 389249 | 0.00 | Why? |
| Cardiovascular Diseases | 1 | 2007 | 11497 | 0.00 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2003 | 9335 | 0.00 | Why? |